Association between genetic polymorphisms in the cyclooxygenase-1 gene promoter and peptic ulcers in Japan

International Journal of Molecular Medicine

Volumn 20, Issue 3, 2007, Pages 373-378

  Arisawa, Tomiyasu ^a   Tahara, Tomomitsu ^a   Shibata, Tomoyuki ^a   Nagasaka, Mitsuo ^a   Nakamura, Masakatsu ^a   Kamiya, Yoshio ^a   Fujita, Hiroshi ^a   Nakamura, Masahiko ^a   Yoshioka, Daisuke ^a   Arima, Yuko ^a   Okubo, Masaaki ^a   Hirata, Ichiro ^a   Nakano, Hiroshi ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cyclooxygenase 1; Gastritis; Gene polymorphism; Non steroidal anti inflammatory drug; Peptic ulcer

Indexed keywords

CYCLOOXYGENASE 1; NONSTEROID ANTIINFLAMMATORY AGENT; PRIMER DNA; PTGS1 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ATROPHY; DUODENUM ULCER; ENZYMOLOGY; FEMALE; GENETIC POLYMORPHISM; GENETICS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; JAPAN; MALE; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PATHOGENICITY; PATHOLOGY; PEPTIC ULCER; PROMOTER REGION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH MUCOSA; STOMACH ULCER;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ATROPHY; BASE SEQUENCE; CYCLOOXYGENASE 1; DNA PRIMERS; DUODENAL ULCER; FEMALE; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; JAPAN; MALE; MIDDLE AGED; PEPTIC ULCER; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); RISK FACTORS; STOMACH ULCER;

EID: 35148859360     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Wolfe MM, Lichtenstein DR and Singh G: Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340: 1888-1899, 1999.
2. Garcia Rodriguez LA and Jick H: Risk of upper gastrointestinal bleeding and perforation associated with individual nonsteroidal anti-inflammatory drugs. Lancet 343: 769-772, 1994.
3. McCarthy DM: Mechanisms of mucosal injury and healing: the role of non-steroidal anti-inflammatory drugs. Scand J Gastroenterol (Suppl) 208: 24-29, 1995.
4. Robert A and Ruwart M: Effect of prostaglandins on the digestive system. In: Prostaglandins. Lee JB (ed). Elsevier, New York, pp113-176, 1982.
5. O'Neal GP and Ford-Hutchinson AW: Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 330: 156-160, 1993.
6. Bombardier C, Laine L, Reicin A, et al: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343: 1520-1528, 2000.
7. Halushka MK, Walker LP and Halushka PV: Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther 73: 122-130, 2003.
8. van Oijen MG, Laheij RJ, Koetsier M, et al: Effect of a specific cyclooxygenase-gene polymorphism (A-842G/C50T) on the occurrence of peptic ulcer hemorrhage. Dig Dis Sci 51: 2348-2352, 2006.
9. Shi J, Misso NL, Duffy DL, et al: Cyclooxygenase-1 gene polymorphisms in patients with different asthma phenotypes and atrophy. Eur Respir J 26: 249-256, 2005.
10. Dixon MF, Genta RM, Yardley JH and Correa P: Classification and grading of gastritis: the updated Sydney system. Am J Surg Pathol 20: 1161-1181, 1996.
11. Arisawa T, Tahara T, Shibata T, et al: The relationship between Helicobacter pylori infection and promoter polymorphism of the Nrf2 gene in chronic gastritis. Int J Mol Med 19: 143-148, 2007.
12. Arisawa T, Tahara T, Shibata T, et al: A polymorphism of microRNA 27a genome region is associated with the development of gastric mucosal atrophy in Japanese male subjects. Dig Dis Sci 52: 1691-1697, 2007.
13. Riva A and Kohane IS: SNPper: retrieval and analysis of human SNPs. Bioinformatics 18: 1681-1685, 2002.
14. Xu XM, Tang JL, Chen X, Wang LH and Wu KK: Involvement of two Sp1 elements in basal endothelial prostaglandin H synthase-1 promoter activity. J Biol Chem 272: 6943-6950, 1997.
15. Heinemeyer T, Wingender E, Reuter I, et al: Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res 26: 362-367, 1998.
16. Gonzalez-Conejero R, Rivera J, Corral J, Acuna C, Guerrero JA and Vicente V: Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? Stroke 36: 276-280, 2005.
17. Maree AO, Curtin RJ, Chubb A, et al: Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 3: 2340-2345, 2005.
18. Lepantalo A, Mikkelsson J, Resendiz JC, et al: Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb Haemost 95: 253-259, 2006.
19. Dajani EZ and Agrawal NM: Prevention of nonsteroidal antiinflammatory drug-induced gastroduodenal ulcers: role of mucosal protective and gastric antisecretory drugs. Dig Dis 13 (suppl 1): 48-61, 1995.
20. Bernersen B, Johnsen R, Straume B, Burhol PG, Jenssen TG and Stakkevold PA: Towards a true prevalence of peptic ulcer: the Sorreisa gastrointestinal disorder study. Gut 31: 989-992, 1990.
21. Laine L, Maller ES, Yu C, Quan H and Simon T: Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology 127: 395-402, 2004.
22. Matsukawa Y, Aoki M, Nishinarita S, et al: Prevalence of Helicobacter pylori in NSAID users with gastric ulcer. Rheumatology 42: 947-950, 2003.
23. Chan FK: NSAID-induced peptic ulcers and Helicobacter pylori infection: implications for patient management. Drug Saf 28: 287-300, 2005.
24. Zapata-Colindres JC, Zepeda-Gomez S, Montano-Loza A, Vazquez-Ballesteros E, de Jesus Villalobos J and Valdovinos-Andraca F: The association of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in peptic ulcer disease. Can J Gastroenterol 20: 277-280, 2006.
25. Ji KY and Hu FL: Interaction or relationship between Helicobacter pylori and non-steroidal anti-inflammatory drugs in upper gastrointestinal diseases. World J Gastroenterol 12: 3789-3792, 2006.
26. Graham DY, Agrawal NM, Campbell DR, et al: Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Int Med 162: 169-175, 2002.
27. Garcia Rodrigues LA and Hernandez-Diaz S: Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 13: 570-576, 2001.
28. Rostom A, Wells G, Tugwell P, Welch V, Dube C and McGowan J: The prevention of chronic NSAID-induced upper gastrointestinal toxicity: a Cochrane collaboration metaanalysis of randomized controlled trials. J Rheumatol 27: 2203-2214, 2000.